17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells

      research-article
      a , a , b , a , a , c , c , c , a , *
      Redox Biology
      Elsevier
      AP-1, activator protein 1, ASK1, apoptosis signal-regulating kinase 1, DHE, Dehydroepiandrosterone, DMEN-F12, Dulbecco's modified eagle medium, DCFH2-DA, 2′-7′- dichlorodihydrofluorescein diacetate, GSH, glutathione, HDA2, Histone deacetylase 2, IAA, iodoacetic acid, IAM, iodoacetamide, MitoSOX, red mitochondrial superoxide indicator, NAC, N-acetyl-cysteine, NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells, PCa, prostate cancer, REF-1, redox factor – 1, TXNIP, thioredoxin-interacting protein, TRX, thioredoxin, TRXR, thioredoxin reductase, Thioredoxin, Thioredoxin reductase, TXNIP, Prostate cancer, Redox signaling, Apoptosis

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Accumulating evidence suggests that natural bioactive compounds, alone or in combination with traditional chemotherapeutic agents, could be used as potential therapies to fight cancer. In this study, we employed four natural bioactive compounds (curcumin, resveratrol, melatonin, and silibinin) and studied their role in redox control and ability to promote apoptosis in androgen sensitive and insensitive prostate cancer cells. Here is shown that curcumin and resveratrol promote ROS production and induce apoptosis in LNCaP and PC-3. An increase in reactive species is a trigger event in curcumin-induced apoptosis and a consequence of resveratrol effects on other pathways within these cells. Moreover, here we demonstrated that these four compounds affect differently one of the main intracellular redox regulator, the thioredoxin system. Exposure to curcumin and resveratrol promoted TRX1 oxidation and altered its subcellular location. Furthermore, resveratrol diminished TRX1 levels in PC-3 cells and increased the expression of its inhibitor TXNIP. Conversly, melatonin and silibinin only worked as cytostatic agents, reducing ROS levels and showing preventive effects against TRX oxidation. All together, this work explores the effect of compounds currently tested as chemo-preventive agents in prostate cancer therapy, on the TRX1 redox state and function. Our work shows the importance that the TRX system might have within the differences found in their mechanisms of action. These bioactive compounds trigger different responses and affect ROS production and redox systems in prostate cancer cells, suggesting the key role that redox-related pathways might play in processes like differentiation or survival in prostate cancer.

          Graphical abstract

          Highlights

          • Resveratrol decreases TRX1 by increasing TXNIP while curcumin induces TRX1 oxidation.

          • Antioxidants decrease TRX1 oxidation and nuclear translocation to prevent cell death.

          • TRX1 oxidation and nuclear translocation play a key role in apoptosis.

          • Differences in the apoptosis induction of bioactive compounds relay on TRX1 oxidation.

          Related collections

          Most cited references55

          • Record: found
          • Abstract: found
          • Article: not found

          Oxidative stress and cancer: an overview.

          Reactive species, which mainly include reactive oxygen species (ROS), are products generated as a consequence of metabolic reactions in the mitochondria of eukaryotic cells. In normal cells, low-level concentrations of these compounds are required for signal transduction before their elimination. However, cancer cells, which exhibit an accelerated metabolism, demand high ROS concentrations to maintain their high proliferation rate. Different ways of developing ROS resistance include the execution of alternative pathways, which can avoid large amounts of ROS accumulation without compromising the energy demand required by cancer cells. Examples of these processes include the guidance of the glycolytic pathway into the pentose phosphate pathway (PPP) and/or the generation of lactate instead of employing aerobic respiration in the mitochondria. Importantly, ROS levels can be used as a thermostat to monitor the damage that cells can bear. The implications for ROS regulation are highly significant for cancer therapy because commonly used radio- and chemotherapeutic drugs influence tumor outcome through ROS modulation. Moreover, the discovery of novel biomarkers that are able to predict the clinical response to pro-oxidant therapies is a crucial challenge to overcome to allow for the personalization of cancer therapies. Copyright © 2012 Elsevier B.V. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Estimates of cancer incidence and mortality in Europe in 2008.

            Up-to-date statistics on cancer occurrence and outcome are essential for the planning and evaluation of programmes for cancer control. Since the relevant information for 2008 is not generally available as yet, we used statistical models to estimate incidence and mortality data for 25 cancers in 40 European countries (grouped and individually) in 2008. The calculations are based on published data. If not collected, national rates were estimated from national mortality data and incidence and mortality data provided by local cancer registries of the same or neighbouring country. The estimated 2008 rates were applied to the corresponding country population estimates for 2008 to obtain an estimate of the numbers of cancer cases and deaths in Europe in 2008. There were an estimated 3.2 million new cases of cancer and 1.7 million deaths from cancer in 2008. The most common cancers were colorectal cancers (436,000 cases, 13.6% of the total), breast cancer (421,000, 13.1%), lung cancer (391,000, 12.2%) and prostate cancer (382,000, 11.9%). The most common causes of death from cancer were lung cancer (342,000 deaths, 19.9% of the total), colorectal cancer (212,000 deaths, 12.3%), breast cancer (129,000, 7.5%) and stomach cancer (117,000, 6.8%). Copyright 2009 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1.

              Apoptosis signal-regulating kinase (ASK) 1 was recently identified as a mitogen-activated protein (MAP) kinase kinase kinase which activates the c-Jun N-terminal kinase (JNK) and p38 MAP kinase pathways and is required for tumor necrosis factor (TNF)-alpha-induced apoptosis; however, the mechanism regulating ASK1 activity is unknown. Through genetic screening for ASK1-binding proteins, thioredoxin (Trx), a reduction/oxidation (redox)-regulatory protein thought to have anti-apoptotic effects, was identified as an interacting partner of ASK1. Trx associated with the N-terminal portion of ASK1 in vitro and in vivo. Expression of Trx inhibited ASK1 kinase activity and the subsequent ASK1-dependent apoptosis. Treatment of cells with N-acetyl-L-cysteine also inhibited serum withdrawal-, TNF-alpha- and hydrogen peroxide-induced activation of ASK1 as well as apoptosis. The interaction between Trx and ASK1 was found to be highly dependent on the redox status of Trx. Moreover, inhibition of Trx resulted in activation of endogenous ASK1 activity, suggesting that Trx is a physiological inhibitor of ASK1. The evidence that Trx is a negative regulator of ASK1 suggests possible mechanisms for redox regulation of the apoptosis signal transduction pathway as well as the effects of antioxidants against cytokine- and stress-induced apoptosis.
                Bookmark

                Author and article information

                Contributors
                Journal
                Redox Biol
                Redox Biol
                Redox Biology
                Elsevier
                2213-2317
                31 March 2017
                August 2017
                31 March 2017
                : 12
                : 634-647
                Affiliations
                [a ]Departamento de Morfologia y Biologia Celular, Biology Unit, Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), Universidad de Oviedo, 33006 Oviedo, Asturias, Spain
                [b ]Research and Development Department, Bioquochem S.L., Parque Tecnológico de Asturias, 33428 Llanera, Asturias, Spain
                [c ]Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolisnka Institute, SE-17177 Stockholm, Sweden
                Author notes
                [* ]Correspondence to: Departamento de Morfología y Biología Celular, Facultad de Medicina, C/Julián Clavería 6, 33006 Oviedo, Spain. sainzrosa@ 123456uniovi.es
                Article
                S2213-2317(16)30437-2
                10.1016/j.redox.2017.03.025
                5385622
                28391184
                893e71dd-4dc3-46c2-b7a9-8bf8ac14761c
                © 2017 The Authors. Published by Elsevier B.V.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 20 December 2016
                : 23 March 2017
                : 24 March 2017
                Categories
                Research Paper

                ap-1, activator protein 1,ask1, apoptosis signal-regulating kinase 1,dhe, dehydroepiandrosterone,dmen-f12, dulbecco's modified eagle medium,dcfh2-da, 2′-7′- dichlorodihydrofluorescein diacetate,gsh, glutathione,hda2, histone deacetylase 2,iaa, iodoacetic acid,iam, iodoacetamide,mitosox, red mitochondrial superoxide indicator,nac, n-acetyl-cysteine,nf-kb, nuclear factor kappa-light-chain-enhancer of activated b cells,pca, prostate cancer,ref-1, redox factor – 1,txnip, thioredoxin-interacting protein,trx, thioredoxin,trxr, thioredoxin reductase,thioredoxin,thioredoxin reductase,txnip,prostate cancer,redox signaling,apoptosis

                Comments

                Comment on this article